Institut für Klinische Krebsforschung

IKF is a leading non-profit clinical research organization specializing in investigator-driven and collaborative industry-academic trials focused on oncology. It has contributed to pivotal studies in NSCLC with EGFR mutations, advanced pancreatic cancer treatment strategies, and novel approaches for multiple myeloma. The institute’s work includes biomarker-driven patient selection through its PLATON molecular profiling network and partnerships with major academic centers across Europe. Its recent trials include head-to-head comparisons of new targeted therapies versus standard-of-care regimens, aiming to improve survival outcomes and quality of life for patients with advanced cancers[1][3][4].